Search by Drug Name or NDC

    NDC 50102-0591-40 MEDROXYPROGESTERONE ACETATE 150 mg/mL Details

    MEDROXYPROGESTERONE ACETATE 150 mg/mL

    MEDROXYPROGESTERONE ACETATE is a INTRAMUSCULAR INJECTION, SUSPENSION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Afaxys Pharma, LLC. The primary component is MEDROXYPROGESTERONE ACETATE.

    Product Information

    NDC 50102-0591
    Product ID 50102-591_8f640668-f6c0-48cc-92bb-94dff0bfad3c
    Associated GPIs 2515003510E620
    GCN Sequence Number 026098
    GCN Sequence Number Description medroxyprogesterone acetate SYRINGE 150 MG/ML INTRAMUSC
    HIC3 G8C
    HIC3 Description CONTRACEPTIVES,INJECTABLE
    GCN 11254
    HICL Sequence Number 001442
    HICL Sequence Number Description MEDROXYPROGESTERONE ACETATE
    Brand/Generic Generic
    Proprietary Name MEDROXYPROGESTERONE ACETATE
    Proprietary Name Suffix n/a
    Non-Proprietary Name MEDROXYPROGESTERONE ACETATE
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, SUSPENSION
    Route INTRAMUSCULAR
    Active Ingredient Strength 150
    Active Ingredient Units mg/mL
    Substance Name MEDROXYPROGESTERONE ACETATE
    Labeler Name Afaxys Pharma, LLC
    Pharmaceutical Class Progesterone Congeners [CS], Progestin [EPC]
    DEA Schedule n/a
    Marketing Category ANDA
    Application Number ANDA210761
    Listing Certified Through 2022-12-31

    Package

    NDC 50102-0591-40 (50102059140)

    NDC Package Code 50102-591-40
    Billing NDC 50102059140
    Package 1 SYRINGE in 1 CARTON (50102-591-40) / 1 mL in 1 SYRINGE
    Marketing Start Date 2020-09-21
    NDC Exclude Flag N
    Pricing Information
    Price Per Unit 38.6207
    Pricing Unit ML
    Effective Date 2024-02-21
    NDC Description MEDROXYPROGESTERONE 150 MG/ML
    Pharmacy Type Indicator C/I
    OTC N
    Explanation Code 1, 5
    Classification for Rate Setting G
    As of Date 2024-02-21
    This pricing file, entitled the NADAC (National Average Drug Acquisition Cost) files, provide state Medicaid agencies with covered outpatient drug prices by averaging survey invoice prices from retail community pharmacies across the United States. These pharmacies include independent retail community pharmacies and chain pharmacies. The prices are updated on a weekly and monthly basis